Human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) can cause severe and lethal bronchiolitis and pneumonia among particularly vulnerable populations, mostly infants, the elderly and immunocompromised patients. Researchers from Vanderbilt University Medical Center have isolated and characterized novel antibodies that cross-neutralize RSV and hMPV.
Human respiratory syncytial virus (hRSV) represents a major global health burden and is a leading cause of severe respiratory disease, particularly among preterm infants. Despite extensive efforts to prevent hRSV infection, currently approved monoclonal antibody (mAb) therapies have been exclusively designed to target its surface fusion or pre-fusion protein (F-hRSV).
Invivyd Inc. has nominated VBY-329 as a preclinical development candidate for the prevention of respiratory syncytial virus (RSV) among neonates, infants and children.
Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have described benzoselenazepine compounds reported to be useful for the respiratory syncytial virus (RSV) infection.
Enanta Pharmaceuticals Inc.’s phase IIb study of zelicapavir missed its primary endpoint in treating respiratory syncytial virus (RSV) but mined enough positive results to get the company to talk about advancing the once-daily oral treatment into further, larger studies.
While U.S. policymakers are scaling back funding on mRNA vaccine research, Australia is accelerating investment in the technology. At the center of this effort is Moderna Inc., which is establishing an mRNA research and manufacturing footprint in the country and banking on decades of local expertise to bring new therapies to the clinic and serve as a regional hub for Asia Pacific.
CSPC Pharmaceutical Group Ltd.’s SYH-2066 tablets has obtained clearance from China’s National Medical Products Administration (NMPA) to enter clinical trials for respiratory infections caused by respiratory syncytial virus (RSV).
It’s not surprising that, of all the recommendations the U.S. CDC’s vaccine advisory board made at its June meeting, the first one Health and Human Services Secretary Robert Kennedy signed off on would essentially remove thimerosal from influenza vaccines in the U.S. What is surprising is the time it took for him to do so, given his long-held position on the preservative used in multidose vials and his insistence that a thimerosal presentation and vote be added to the agenda.
With no U.S. CDC director in place yet, Health and Human Services Secretary Robert Kennedy recently adopted two vaccine recommendations from the April meeting of the Advisory Committee for Immunization Practices (ACIP), making them official CDC recommendations and ensuring coverage of the vaccines for the specified populations.
